louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04100707: Efficacy of Genicular Nerve Radiofrequency
Official title: Efficacy of Genicular Nerve Radiofrequency in Patients With Knee Pain After Total Knee Replacement
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Pain
Keywords: Genicular nerve
Knee pain
Ultrasound
Lead sponsor: Diskapi Teaching and Research Hospital
Sponsor class: OTHER
First posted: 2019-09-24
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In patients with knee pain, local anesthetics and radiofrequency applications to superolateral, superomedial and inferomedial genicular nerves that innervate the knee joint are also preferred methods besides analgesic and physical therapy. When necessary, total knee replacement is the preferred method for primary knee arthrosis.

However, continuing knee pain is reported in approximately 20% of patients after total knee replacement. In similar cases; In the painful knees, the blockages of the genicular nerves are successfully applied.

In this study; the efficacy of imaging-guided radiofrequency application will be investigated in patients presenting with knee pain after total knee replacement.

Detailed description: Although simple analgesic and physical therapy methods are applied, some patients suffer from pain. Genicular nerve blocks and radiofrequency methods are performed usually for this reason. This procedure is performed with ultrasound and / or fluoroscopy, sterile staining and covering of painful knee to the middle of thigh and leg, localization of superomedial, superolateral, inferomedial genicular nerves are tested and then conventional radiofrequency is applied to all 3 nerve regions.Fifty patients who had total knee prosthesis for gonarthrosis in the Orthopedics and Traumatology Clinic at least 3 months postoperatively had knee pain (infection, mechanical causes and radicular pain) were included in the study.The VAS and WOMAC values recorded at the time of application and the VAS and WOMAC values recorded at the 1st week, 1st month and 3rd month after the procedure will be used to evaluate the effectiveness of the method.

Eligibility criteria: Inclusion Criteria:

* knee pain

Exclusion Criteria:

* with communication problems (VAS and WOMAC scores could not be evaluated)
* infectious-mechanical pain-related conditions,
* with radicular pain

Primary outcomes:
measure: Post intervention analgesic effect
timeFrame: at first 3 months
Secondary outcomes:
measure: Ultrasound versus fluoroscopy
timeFrame: at first 3 months
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Diskapi Teaching and Research Hospital
Study officials:
References:
Clinical trial NCT02375607: Could Algometric Assessment be Effective to Adjust Postoperative Analgesic Requirement?
Official title: Could Algometric Assessment be Effective to Adjust Postoperative Analgesic Requirement?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pain
Keywords: Pain management
Lead sponsor: Tokat Gaziosmanpasa University
Sponsor class: OTHER
First posted: 2015-03-02
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The purpose of this study is to determine the correlation between preoperative algometer score and the amount of postoperative analgesic consumption. The algometer score of the patients will be recorded in the preoperative period. In postoperative period, the analgesic consumption rate will record and compare with the algometer score.

Detailed description: The aim of this study is to define the correlation between preoperative algometer score and the analgesic consumption rate. A total of 80 patients whose undergo septoplasty or septorhinoplasty will be included in this study. After preoperative examination, a positive pressure using algometer device will be performed until minimal pain is felt. In postoperative period, the amount of analgesic consumption of the patient will record and compare with the algometer score.

Eligibility criteria: Inclusion Criteria:

* Patients those undergo septoplasty or septorhinoplasty

Exclusion Criteria:

* Hypertension
* Diabetes mellitus type 1 or 2
* Continuous use of analgesics
* Patients whose do not accept to participate in the study
* Patients those reoperated for bleeding

Primary outcomes:
measure: Algometer score
timeFrame: In one hour before the operation up to 3 years
Secondary outcomes:
measure: Analgesic consumption
timeFrame: In the first 24 hours after the operation up to 3 years
Other outcomes:
Locations:
city: Tokat
country: Turkey
facility: Gaziosmanpasa University
Study officials:
affiliation: Gaziosmanpasa University, Medical Faculty, Department of Anesthesiology and Reanimation
name: ZIYA KAYA, Assoc.Prof.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hsu YW, Somma J, Hung YC, Tsai PS, Yang CH, Chen CC. Predicting postoperative pain by preoperative pressure pain assessment. Anesthesiology. 2005 Sep;103(3):613-8. doi: 10.1097/00000542-200509000-00026.
Clinical trial NCT06252207: Desflurane Versus Isoflurane for Speeding Postanesthetic Recovery and Hospital Discharge
Official title: Desflurane Versus Isoflurane for Speeding Postanesthetic Recovery and Hospital Discharge: a Cluster Randomized Crossover Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Surgery
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
First posted: 2024-02-09
Enrollment: 2619
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Randomized cluster cross-over trial
Primary purpose: OTHER

Brief summary: The investigators thus propose a comparative effectiveness quality improvement project to evaluate the feasibility of switching from near-exclusive use of isoflurane in adult general surgical patients to Desflurane.

Detailed description: The three available volatile anesthetics appear to be comparably safe. However, higher solubility slows emergence from isoflurane and sevoflurane compared to Desflurane. Even a few minutes delay in emergence from anesthesia has financial implications since institutional costs of operating room time can easily be $30 per minute. Postoperative care is also expensive. Furthermore, in busy hospitals such as the Cleveland Clinic, inadequate recovery throughput frequently delays surgery.

The investigators thus propose a comparative effectiveness quality improvement project to evaluate the feasibility of switching from near-exclusive use of isoflurane in adult general surgical patients to Desflurane. (The investigators will exclude children because there are compelling clinical reasons to use sevoflurane in pediatric patients.) The proposed comparison is between isoflurane (our current routine) and Desflurane which is no longer used at the Clinic because of price concerns - a decision that that did not consider down-stream effects, including prolonged emergence and recovery.

Eligibility criteria: Inclusion Criteria:

* Adults having general anesthesia in the G operating room suite at the Cleveland Clinic Main Campus.

Exclusion Criteria:

* Operations lasting \<1.5 hours.

Primary outcomes:
measure: Duration of post-anesthesia care unit recovery
timeFrame: 1 hour
Secondary outcomes:
measure: Duration of anesthetic emergence
timeFrame: 1 hour
measure: Cost of post-anesthesia care unit.
timeFrame: 2 hours
measure: Delirium
timeFrame: 5 days
Other outcomes:
Locations:
Study officials:
affiliation: The Cleveland Clinic
name: Allen Keebler, D.O.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01680107: D-cycloserine Augmented CBT for Panic Disorder
Official title: The Effect of a Single-dose of D-cycloserine on the Basic Effects of Cognitive-behaviour Therapy for Panic Disorder - a Randomized Placebo-controlled Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Panic Disorder
Keywords: d-cycloserine, cognitive-behaviour therapy, panic disorder
Lead sponsor: University of Oxford
Sponsor class: OTHER
Collaborators: name: Medical Research Council
First posted: 2012-09-06
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine whether d-cycloserine augments the clinical effects of exposure-based cognitive-behaviour therapy for panic disorder.


Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of panic disorder
* at least moderate agoraphobic avoidance

Exclusion Criteria:

* psychoactive medication last 6 weeks
* exposure-based cognitive-behaviour treatment for panic disorder and agoraphobia during last 3 months
* female participant who is pregnant or breast-feeding
* lifetime history of psychosis, bipolar disorder, alcohol, medication or drug abuse or dependence; current primary depressive disorder
* lifetime history of epilepsy or other significant disease or disorder

Primary outcomes:
measure: self-reported and clinician-rated anxiety and depression measures
timeFrame: 6 months
Secondary outcomes:
measure: emotional information processing
timeFrame: 1 day
Other outcomes:
Locations:
city: Oxford
country: United Kingdom
facility: Department of Psychiatry, University of Oxford
Study officials:
affiliation: University of Oxford
name: Andrea Reinecke, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Oxford
name: Catherine Harmer, PhD
role: STUDY_DIRECTOR
References:
citation: Reinecke A, Nickless A, Browning M, Harmer CJ. Neurocognitive processes in d-cycloserine augmented single-session exposure therapy for anxiety: A randomized placebo-controlled trial. Behav Res Ther. 2020 Jun;129:103607. doi: 10.1016/j.brat.2020.103607. Epub 2020 Mar 19.
Clinical trial NCT05060107: Intra-articular Injection of MSC-derived Exosomes in Knee Osteoarthritis (ExoOA-1)
Official title: A Phase I Study Aiming to Assess Safety and Efficacy of a Single Intra-articular Injection of MSC-derived Exosomes (CelliStem®OA-sEV) in Patients With Moderate Knee Osteoarthritis (ExoOA-1)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Osteoarthritis, Knee
Lead sponsor: Universidad de los Andes, Chile
Sponsor class: OTHER
First posted: 2021-09-28
Enrollment: 10
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study aim to evaluate safety of exosomes (sEVs) from allogeneic mesenchymal stromal cells delivered by an intra-articular injection in the knee of patients with mild to moderate symptomatic osteoarthritis. The sEVs will be produced in a GMP-facility. We expect to enrolle 10 patients in this phase 1 trial and the follow-up will be up to 12 months.


Eligibility criteria: Inclusion Criteria:

* Symptomatic knee OA with VAS \>50mm
* Knee OA Kellgren-Lawrence grade II to III
* Chondromalacia grade I to III
* Stable joint

Exclusion Criteria:

* Bilateral symptomatic knee OA
* Local infection
* Neoplasia
* Joint replacement
* Recent use of local steroids
* BMI \> 30

Primary outcomes:
measure: Adverse Event
timeFrame: 12 months
Secondary outcomes:
measure: Incidence of injection-related pain according to VAS scale (0-100mm)
timeFrame: 1 week
measure: Incidence of injection-related sinovitis according to effusion grading scale of knee joint
timeFrame: 1 week
measure: Pain reduction
timeFrame: 52 weeks
measure: Disability reduction
timeFrame: 52 weeks
measure: Percentage of responders
timeFrame: 52 weeks
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01576107: MOTIVACTION - Study
Official title: Motivational Intervention Enhancing Physical Activity In Oncology Patients (MOTIVACTION)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cancer
Keywords: Different cancer entities
Lead sponsor: German Cancer Research Center
Sponsor class: OTHER
Collaborators: name: Heidelberg University
First posted: 2012-04-12
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Impact of a 4-week exercise intervention vs. a stress-management-training on physical activity (measured objectively and by questionnaire) of cancer patients of different entities and out-patient regimes.


Eligibility criteria: Inclusion Criteria:

* Physical activity \< 150 minutes /week
* Patients are currently receiving outpatient treatment (acute or maintenance therapy) or finished this therapy not longer than six months ago

Exclusion Criteria:

* Serious Orthopedic limitations
* Serious neurological disorders
* Serious cardiovascular diseases
* Bone metastases
* wound healing / scarring not completed
* Rehabilitation during the next eight weeks

Primary outcomes:
measure: Physical activity (accelerometer, Actigraph)
timeFrame: 4 weeks
Secondary outcomes:
measure: physical activity (Short QUestionnaire to ASsess Healthenhancing physical activity, SQUASH)
timeFrame: 4 weeks, 3 months
measure: Self-Efficacy for Managing Chronic Disease 6-Item Scale (SES6G)
timeFrame: 4 weeks, 3 months
measure: Quality of life (EORTC QLQ C30)
timeFrame: 4 weeks, 3 months
measure: variables of the Health Action Process Approach
timeFrame: 4 weeks, 3 months
measure: Barriers and barrier management in physical exercise
timeFrame: 4 weeks, 3 months
measure: Exercise experience
timeFrame: 4 weeks, 3 Months
Other outcomes:
Locations:
city: Heidelberg
country: Germany
facility: National Center for Tumor Diseases (German Cancer Research Center)
state: Baden-Württemberg
city: Heidelberg
country: Germany
facility: National Center for Tumor Diseases
state: Baden-Württemberg
Study officials:
affiliation: German Cancer Research Center
name: Joachim Wiskemann, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ungar N, Wiskemann J, Sieverding M. Physical Activity Enjoyment and Self-Efficacy As Predictors of Cancer Patients' Physical Activity Level. Front Psychol. 2016 Jun 21;7:898. doi: 10.3389/fpsyg.2016.00898. eCollection 2016.
Clinical trial NCT04116307: Enteroadsorbent Polymethylsiloxane vs Probiotic Lactobacillus Reuteri in the Treatment of Rotaviral Gastroenteritis
Official title: Comparison of Clinical Efficacy of Enteroadsorbent Polymethylsiloxane vs Probiotic Lactobacillus Reuteri in the Treatment of Rotaviral Gastroenteritis in Infants and Toddlers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Rotavirus Gastroenteritis
Lead sponsor: University Hospital for Infectious Diseases, Croatia
Sponsor class: OTHER
First posted: 2019-10-04
Enrollment: 130
Sex: ALL
Minimum age (years): 6
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates a new drug, new enteroadsorbent polymethylsiloxane (Enterosgel) in the treatment of rotavirus gastroenteritis in children. Half of the participants received a new drug, polymethylsiloxane and half of the participants received standard treatment - probiotic L. reuteri (BioGaia).

Detailed description: Polymethylsiloxane and probiotic L. reuteri both hasten symptoms of the rotavirus gastroenteritis but they do so by a different mode of action.

Polymethylsiloxane is an enteroadsorbent and it possibly acts by adsorption of viruses and doing so it prevents binding rotaviruses for enterocytes. Another mode of action can be forming a thin layer over the mucosal surfaces thus protects them from various damaging factors.

Probiotics help the healing of the intestinal mucosa presumably in few ways - by normalization of gut flora, by competition with pathogen bacteria for binding sites and nutrients and by stimulation of intestinal immune system.

Eligibility criteria: Inclusion Criteria:

1. age 6-36 months
2. proven rotavirus gastroenteritis
3. symptom duration less than 48 hours
4. informed consent of the parents/caregivers

Exclusion Criteria:

1. rotavirus vaccination
2. rotavirus infection in a patient's history
3. severe acute or chronic illness with possible influence on rotavirus gastroenteritis outcome

Primary outcomes:
measure: Gastroenteritis symptoms duration.
timeFrame: 1-8 days.
Secondary outcomes:
measure: Duration of the hospitalization of any kind.
timeFrame: 30 days
measure: Total number of loose stools.
timeFrame: 8 days
Other outcomes:
Locations:
city: Zagreb
country: Croatia
facility: University Clinic for Infectious Diseases
Study officials:
affiliation: University Clinic for Infectious Diseases, Zagreb
name: Goran Tešović, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Markovinovic L, Knezovic I, Kniewald T, Stemberger Maric L, Trkulja V, Tesovic G. Enteroadsorbent Polymethylsiloxane Polyhydrate vs. Probiotic Lactobacillus reuteri DSM 17938 in the Treatment of Rotaviral Gastroenteritis in Infants and Toddlers, a Randomized Controlled Trial. Front Pediatr. 2020 Dec 21;8:553960. doi: 10.3389/fped.2020.553960. eCollection 2020.
Clinical trial NCT01086007: Pain Related Sexual Dysfunction After Laparoscopic Inguinal Hernia Repair
Official title: Pain Related Sexual Dysfunction After Laparoscopic Inguinal Hernia Repair
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sexual Dysfunction
Hernia, Inguinal
Other Chronic Postoperative Pain
Keywords: Groin hernia
chronic pain
Persistent postoperative pain
Laparoscopic inguinal herniotomy
Sexual dysfunction
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
Collaborators: name: Innovative Medicines Initiative
First posted: 2010-03-12
Enrollment: 1172
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who have had a laparoscopic inguinal hernia repair

Brief summary: Previous studies have reported that about 3 % of patients who have had open inguinal herniorrhaphy had a visceral, ejaculatory-related pain.

The investigators want to assess this problem among patients after laparoscopic inguinal hernia repair with(self-administered questionnaire study).


Eligibility criteria: Inclusion Criteria:

* Male patients
* \>18 yrs

Exclusion Criteria:

* Research protection

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen East
country: Denmark
facility: Section of Surgical Pathophysiology, Rigshospitalet
Study officials:
affiliation: Section of Surgical Pathophysiology, Rigshospitalet
name: Gitte Linderoth, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06340607: Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients
Official title: Impact of Neohepatic Albumin-Bilirubin Scores on Renal Outcomes Following Living-donor Liver Transplantation: Propensity Score Analysis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Kidney Injury
Chronic Kidney Diseases
Graft Failure
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2024-04-01
Enrollment: 3422
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: living donor liver transplantation recipients at Asan Medical Center, Seoul, Korea from January 2012 to December 2019

Brief summary: This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.

Detailed description: Acute kidney injury (AKI) after liver transplantation (LT) significantly affects patient and graft outcomes. The Albumin-Bilirubin (ALBI) score, an objective and sensitive index of liver function, has potential applicability in predicting outcomes following LT. This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.

Eligibility criteria: Inclusion Criteria:

* living donor liver transplantation recipients (≥18 years)

Exclusion Criteria:

* preoperative serum creatinine (sCr) \> 1.4 mg/dL, diagnosed CKD or hepatorenal syndrome (HRS), or hemodialysis at baseline

Primary outcomes:
measure: acute kidney injury
timeFrame: within 7 days after surgery
Secondary outcomes:
measure: chronic kidney injury
timeFrame: within 1 year after surgery
measure: graft failure
timeFrame: the graft failure at overall period (calculated from the date of surgery to the last follow-up) from the date of surgery (up to 10 years)]
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
state: Song-pa Gu
Study officials:
References:
Clinical trial NCT01126307: Study of Verapamil in Refractory Epilepsy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Epilepsy
Seizures
Keywords: refractory epilepsy- greater than 4 seizures in 2 month baseline period
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2010-05-19
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Epilepsy is one of the most common chronic neurological diseases, affecting 300,000 Canadians. One in 3 epilepsy patients have refractory seizures meaning that all antiseizure drugs fail to control their seizures. This drug resistance in epilepsy may be related to the over expression of multidrug resistance proteins (MDR). Varapamil inhibits MDR. We propose to add verapamil/placebo to patients' anti epilepsy medication for 3 months. Patients who receive placebo will have verapamil added for 3 months after the completion of the double-blind treatment period. Seizure frequency/severity will be tracked. Blood samples for DNA will be collected. There will be 9 clinic visits over 32 weeks. ECG and echocardiogram will be done at baseline and repeated if necessary

Detailed description: This open label study will consist of three phases: baseline, Double-blind treatment and open-label-treatment. There are 9 visits over 32 weeks. During the baseline period, the number of seizures will be recorded during 2 months while the patient is on a dose of antiseizure drug(s) that was previously established to provide better seizure control. Blood work, including blood for DNA baseline ECG and echocardiogram will be done and may be repeated if necessary. During the 3 months of double-blind treatment phase, verapamil/placebo will be added to the current medications. Visits are every 4 weeks. Vital signs, seizure counts and adverse events will be evaluated. All patients who received placebo will be offered 3 months of open-label treatment with verapamil.

Eligibility criteria: Inclusion Criteria:

* 1. patients in whom seizures are not controlled by their antiseizure medication;
* 2. must have at least 2 seizures per month.

Exclusion Criteria:

* Exclusion: patients with cardiovascular problems that could be adversely affected by verapamil

Primary outcomes:
measure: percentage reduction of seizure frequency
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Toronto Western Hospital
state: Ontario
Study officials:
References: